Trial Profile

The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms The TRAP-2 Study; TRAP-2

04 Nov 2022 Planned number of patients changed from 376 to 388 as per trial design , presented at the 47th European Society for Medical Oncology Congress
13 Sep 2022 Trial design, presented at the 47th European Society for Medical Oncology Congress
18 Jun 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com